Compare TS & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TS | GEHC |
|---|---|---|
| Founded | 2001 | 1892 |
| Country | Luxembourg | United States |
| Employees | 24875 | N/A |
| Industry | Steel/Iron Ore | Computer Software: Prepackaged Software |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.8B | 29.1B |
| IPO Year | N/A | 2022 |
| Metric | TS | GEHC |
|---|---|---|
| Price | $57.04 | $61.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $58.80 | ★ $88.38 |
| AVG Volume (30 Days) | 1.3M | ★ 4.2M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.80% | 0.24% |
| EPS Growth | N/A | ★ 4.84 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $20,625,000,000.00 |
| Revenue This Year | $1.53 | $7.12 |
| Revenue Next Year | $3.59 | $4.45 |
| P/E Ratio | ★ $12.59 | $72.47 |
| Revenue Growth | N/A | ★ 4.84 |
| 52 Week Low | $33.71 | $58.75 |
| 52 Week High | $64.60 | $89.77 |
| Indicator | TS | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 41.63 |
| Support Level | $57.16 | $60.80 |
| Resistance Level | $60.01 | $64.99 |
| Average True Range (ATR) | 1.42 | 1.80 |
| MACD | -0.55 | -0.06 |
| Stochastic Oscillator | 8.56 | 27.20 |
Tenaris SA is engaged in the manufacture and supply of steel pipe products and related services for the energy industry and other industrial applications. The company has one reportable segment, Tubes, which includes the production and sale of steel tubular products such as OCTG, line pipe, and mechanical and structural tubes, mainly for the oil and gas industry. It operates an integrated network of manufacturing, research, and service facilities across the Americas, Europe, the Middle East, Asia, and Africa.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).